Table of Contents

Articles

• Iron Metabolism & its Disorders

  • Open Access

    Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin

    Maciej W. Garbowski, Patricia Evans, Evangelia Vlachodimitropoulou, Robert Hider, John B. Porter

    Haematologica October 2017 102: 1640-1649; doi:10.3324/haematol.2017.170605

    • Garbowski et al. Supplementary Appendix
    • Disclosures and Contributions

• Blood Transfusion

  • Open Access

    Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance

    Simona Stivala, Sara Gobbato, Laura Infanti, Martin F. Reiner, Nicole Bonetti, Sara C. Meyer, Giovanni G. Camici, Thomas F. Lüscher, Andreas Buser, Jürg H. Beer

    Haematologica October 2017 102: 1650-1660; doi:10.3324/haematol.2017.164137

    • Stivala et at. Graphical Abstract
    • Stivala et al. Supplementary Appendix
    • Disclosures and Contributions

• Platelet Biology & its Disorders

  • Open Access

    Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

    Rashmi Kanagal-Shamanna, Sanam Loghavi, Courtney D. DiNardo, L. Jeffrey Medeiros, Guillermo Garcia-Manero, Elias Jabbour, Mark J. Routbort, Rajyalakshmi Luthra, Carlos E. Bueso-Ramos, Joseph D. Khoury

    Haematologica October 2017 102: 1661-1670; doi:10.3324/haematol.2017.167726

    • Kanagal-Shamanna et al. Supplementary Appendix
    • Disclosures and Contributions

• Bone Marrow Failure

  • Open Access

    Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1

    Jennifer Vandooren, Wannes Swinnen, Estefania Ugarte-Berzal, Lise Boon, Daphne Dorst, Erik Martens, Ghislain Opdenakker

    Haematologica October 2017 102: 1671-1682; doi:10.3324/haematol.2017.168799

    • Vandooren et al. Supplementary Appendix
    • Disclosures and Contributions
  • Open Access

    Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011

    Krista Vaht, Magnus Göransson, Kristina Carlson, Cecilia Isaksson, Stig Lenhoff, Anna Sandstedt, Bertil Uggla, Jacek Winiarski, Per Ljungman, Mats Brune, Per-Ola Andersson

    Haematologica October 2017 102: 1683-1690; doi:10.3324/haematol.2017.169862

    • Vaht et al. Supplementary Appendix
    • Disclosures and Contributions
  • Open Access

    Rapamycin is highly effective in murine models of immune-mediated bone marrow failure

    Xingmin Feng, Zenghua Lin, Wanling Sun, Maile K. Hollinger, Marie J. Desierto, Keyvan Keyvanfar, Daniela Malide, Pawel Muranski, Jichun Chen, Neal S. Young

    Haematologica October 2017 102: 1691-1703; doi:10.3324/haematol.2017.163675

    • Feng et al. Graphical Abstract
    • Feng et al. Supplementary Appendix
    • Disclosures and Contributions

• Chronic Myeloid Leukemia

  • Open Access

    Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents

    Frédéric Millot, Joëlle Guilhot, Meinolf Suttorp, Adalet Meral Güneş, Petr Sedlacek, Eveline De Bont, Chi Kong Li, Krzysztof Kalwak, Birgitte Lausen, Srdjana Culic, Michael Dworzak, Emilia Kaiserova, Barbara De Moerloose, Farah Roula, Andrea Biondi, André Baruchel

    Haematologica October 2017 102: 1704-1708; doi:10.3324/haematol.2017.170035

    • Disclosures and Contributions

• Acute Myeloid Leukemia

  • Open Access

    Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

    Naval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce, Kenneth Vaughan, Jing Ning, Graciela M. Nogueras González, Keyur Patel, Jeffery Jorgensen, Naveen Pemmaraju, Tapan Kadia, Marina Konopleva, Michael Andreeff, Courtney DiNardo, Jorge Cortes, Renee Ward, Adam Craig, Farhad Ravandi

    Haematologica October 2017 102: 1709-1717; doi:10.3324/haematol.2017.168732

    • Daver et al. Supplementary Appendix
    • Disclosures and Contributions
  • Open Access

    Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients

    Etienne De Clara, Morgane Gourvest, Hanjing Ma, François Vergez, Marie Tosolini, Sébastien Dejean, Cécile Demur, Eric Delabesse, Christian Recher, Christian Touriol, Maria Paola Martelli, Brunangelo Falini, Pierre Brousset, Marina Bousquet

    Haematologica October 2017 102: 1718-1726; doi:10.3324/haematol.2017.171645

    • De Clara et al. Supplementary Appendix
    • Disclosures and Contributions

• Acute Lymphoblastic Leukemia

  • Open Access

    Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951

    Veerle Mondelaers, Stefan Suciu, Barbara De Moerloose, Alina Ferster, Françoise Mazingue, Geneviève Plat, Karima Yakouben, Anne Uyttebroeck, Patrick Lutz, Vitor Costa, Nicolas Sirvent, Emmanuel Plouvier, Martine Munzer, Maryline Poirée, Odile Minckes, Frédéric Millot, Dominique Plantaz, Philip Maes, Claire Hoyoux, Hélène Cavé, Pierre Rohrlich, Yves Bertrand, Yves Benoit

    Haematologica October 2017 102: 1727-1738; doi:10.3324/haematol.2017.165845

    • Mondelaers et al. Supplementary Appendix
    • Disclosures and Contributions
  • Open Access

    Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia

    Benjamin Kobitzsch, Nicola Gökbuget, Stefan Schwartz, Richard Reinhardt, Monika Brüggemann, Andreas Viardot, Ralph Wäsch, Michael Starck, Eckhard Thiel, Dieter Hoelzer, Thomas Burmeister

    Haematologica October 2017 102: 1739-1747; doi:10.3324/haematol.2016.161273

    • Kobitzsch et al. Supplementary Appendix
    • Disclosures and Contributions

• Hodgkin Lymphoma

  • Open Access

    Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials

    Dennis A. Eichenauer, Ingrid Becker, Ina Monsef, Nicholas Chadwick, Vitaliana de Sanctis, Massimo Federico, Catherine Fortpied, Alessandro M. Gianni, Michel Henry-Amar, Peter Hoskin, Peter Johnson, Stefano Luminari, Monica Bellei, Alessandro Pulsoni, Matthew R. Sydes, Pinuccia Valagussa, Simonetta Viviani, Andreas Engert, Jeremy Franklin

    Haematologica October 2017 102: 1748-1757; doi:10.3324/haematol.2017.167478

    • Eichenauer et al. Graphical Abstract
    • Disclosures and Contributions
    • Eichenauer et al. Supplementary Appendix

• Non-Hodgkin Lymphoma

  • Open Access

    Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma

    Laurent Jallades, Lucile Baseggio, Pierre Sujobert, Sarah Huet, Kaddour Chabane, Evelyne Callet-Bauchu, Aurélie Verney, Sandrine Hayette, Jean-Pierre Desvignes, David Salgado, Nicolas Levy, Christophe Béroud, Pascale Felman, Françoise Berger, Jean-Pierre Magaud, Laurent Genestier, Gilles Salles, Alexandra Traverse-Glehen

    Haematologica October 2017 102: 1758-1766; doi:10.3324/haematol.2016.160192

    • Jallades et al. Graphical Abstract
    • Jallades et al. Supplementary Appendix
    • Disclosures and Contributions

• Plasma Cell Disorders

  • Open Access

    Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

    María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, Markus Hansson, Irwindeep Sandhu, Ludek Pour, Luísa Viterbo, Sharon R. Jackson, Anne-Marie Stoppa, Peter Gimsing, Mehdi Hamadani, Gabriela Borsaru, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Helgi van de Velde, Paul G. Richardson, Philippe Moreau

    Haematologica October 2017 102: 1767-1775; doi:10.3324/haematol.2017.170118

    • Mateos et al. Graphical Abstract
    • Mateos et al. Supplementary Appendix
    • Disclosures and Contributions
  • Open Access

    The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

    Tania Díaz, Vanina Rodríguez, Ester Lozano, Mari-Pau Mena, Marcos Calderón, Laura Rosiñol, Antonio Martínez, Natalia Tovar, Patricia Pérez-Galán, Joan Bladé, Gaël Roué, Carlos Fernández de Larrea

    Haematologica October 2017 102: 1776-1784; doi:10.3324/haematol.2017.164632

    • Diaz et al. Supplementary Appendix
    • Disclosures and Contributions

• Cell Therapy & Immunotherapy

  • Open Access

    Notch2 blockade enhances hematopoietic stem cell mobilization and homing

    Weihuan Wang, Shuiliang Yu, Jay Myers, Yiwei Wang, William W. Xin, Marwah Albakri, Alison W. Xin, Ming Li, Alex Y. Huang, Wei Xin, Christian W. Siebel, Hillard M. Lazarus, Lan Zhou

    Haematologica October 2017 102: 1785-1795; doi:10.3324/haematol.2017.168674

    • Wang et al. Supplementary Appendix
    • Disclosures and Contributions

• Complications in Hematology

  • Open Access

    Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

    Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger

    Haematologica October 2017 102: 1796-1805; doi:10.3324/haematol.2017.171041

    • Brown et al. Supplementary Appendix
    • Disclosures and Contributions